All In Biotech

Free tool

FAERS Monitor: Anzupgo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219155 or its brand name (Anzupgo, Delgocitinib). Reports on generic versions are filed under their own applications.

Reports

269

Serious

85

32% of reports

Hospitalization

38

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product use in unapproved indication58
  • pruritus30
  • dermatitis atopic25
  • drug ineffective22
  • dermatitis21
  • erythema20
  • rash17
  • burning sensation13
  • dry skin13
  • eczema13
  • skin burning sensation10
  • skin exfoliation10
  • off label use9
  • erythema multiforme8
  • condition aggravated6

Reports by year received

View as table
YearReports
20201
20215
20227
20238
202414
202589
2026145

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,890 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dermatitisSignal2178.452.01,529
erythema multiformeSignal867.133.9457
dermatitis atopicSignal2537.125.5844
eczemaSignal1319.411.4210
product use in unapproved indicationSignal5818.314.6942
burning sensationSignal1314.58.5151
skin burning sensationSignal1010.95.981
skin exfoliationSignal109.35.066
dry skinSignal137.64.569
erythemaSignal207.65.0109
pruritusSignal306.14.4125
rashSignal173.01.922
condition aggravated61.50.71
drug ineffective221.30.91
off label use90.80.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.